Healthcare

IDEXX raised its 2026 outlook for revenue to USD 4.741 billion to USD 4.767 billion, organic growth to 9.3% to 10.0% and earnings to USD 14.96 to USD 15.16. The operating margin range of 32.1% to 32.3% is lower than the 32.3% to 32.5% …

Tempus sells genomic tests to doctors and licenses de-identified clinical and molecular data to drug makers, which use it to design trials. The two lines feed each other: tests add data, and data licensing carries high margins. Published coverage cites a collaboration with a …

SIG reported FY26 revenue of AUD 10.835 billion, compared with pro-forma FY25 revenue of AUD 9.380 billion. Normalised EBIT increased from AUD 903.4 million to AUD 1,090.0 million, representing 20.6% growth. The EBIT margin advanced from approximately 9.6% to 10.1%.

Total operating revenue rose from NZD 2,021.0 million in FY25 to NZD 2,308.4 million in FY26, an increase of 14% on a reported basis and 12% in constant currency. Profit after tax increased from NZD 377.2 million to NZD 468.5 million.

FY26 reported revenue increased to AUD 261.7 million from AUD 213.0 million. Underlying EBIT rose to AUD 196.1 million from AUD 157.7 million, with theMarginmoving from 74.0% to 74.9%.

Revenue increased from USD 1.336 billion in Q1 FY26 to USD 1.415 billion in Q1 FY27, representing 6% reported growth. The company cited continuedDemandfor sleep devices, masks and related accessories. Core constant-currency growth was 7%, excluding specified portfolio changes.

Revenue from contracts with customers reached AUD 18.6 billion in FY26, an increase of 4.2% on a constant-currency basis. Underlying NPAT excluding non-recurring items was AUD 364.1 million, rising 22.9% in constant currency.